« Return to News | Drug Sponsors

Sorrento Therapeutics completes IgDraSol merger

Wednesday, September 11, 2013 01:31 PM

Sorrento Therapeutics has completed its merger with Igdrasol, a privately-held company focused on the development of cancer therapeutics. Igdrasol shareholders will receive the equivalent of 3,047,968 million shares of Sorrento's common stock. Reflecting Sorrento's recent reverse stock split, and based on the closing share price on Sept. 6, 2013, the transaction is valued at $28.2 million.

Sorrento's drug development pipeline now features late-stage compound Cynviloq, a next-generation nanoparticle formulation of paclitaxel for the potential treatment of metastatic breast cancer, non-small cell lung cancer, pancreatic cancer and other solid tumors. In July, the FDA Division of Oncology Products 1 agreed the data available are sufficient to support a 505(b)(2) pathway, using Abraxane and Taxol as the Reference Listed Drugs, to obtain approval. Sorrento anticipates initiating the single bioequivalence trial required for registration in the fourth quarter.

Dr. Vuong Trieu,  former chief executive officer of Igdrasol, was appointed chief scientific officer of Sorrento; George Uy,  former chief commercial officer of Igdrasol, was appointed chief commercial officer of Sorrento; and two directors were added to Sorrento’s board: Trieu and Jaisim Shah, chief business officer of Protein Design Labs.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.